EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

A novel multiple marker microarray analyzer and methodology to predict major obstetric syndromes using surface markers of circulating extracellular vesicles from maternal plasma

Malene Møller Jørgensen iD, Rikke Bæk, Jenni K Sloth, Rami Sammour, Adi Sharabi-Nov, Manu Vatish iD, Hamutal Meiri iD, Marei Sammar

Acta Obstetricia et Gynecologica Scandinavica · 2025

DOI: 10.1111/aogs.15020 ↗

At a glance

Journal article in Acta Obstetricia et Gynecologica Scandinavica, 2025. Written by Malene Møller Jørgensen and 7 co-authors. Institution: Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark. Major MEDLINE topics: Extracellular Vesicles, Biomarkers, Pre-Eclampsia. Cited 6 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: COST Action, Braude College of Engineering, Research Collaboration Program.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Introduction

Placental‐derived extracellular vesicles (EVs) are nano‐organelles that facilitate intercellular communication between the feto‐placental unit and the mother. We evaluated a novel Multiple Microarray analyzer for identifying surface markers on plasma EVs that predict preterm delivery and preeclampsia compared to term delivery controls. Material and Methods In this prospective exploratory cohort study pregnant women between 24 and 40 gestational weeks with preterm delivery ( n = 16), preeclampsia ( n = 19), and matched term delivery controls ( n = 15) were recruited from Bnai Zion Medical Center, Haifa, Israel. Plasma samples were tested using a multiple microarray analyzer. Glass slides with 17 antibodies against EV surface receptors ‐ were incubated with raw plasma samples, detected by biotinylated secondary antibodies specific to EVs or placental EVs (PEVs), and labeled with cyanine 5–streptavidin. PBS and whole human IgG served as controls. The fluorescent signal ratio to negative controls was log 2 transformed and analyzed for sensitivity and specificity using the area under the receiver operating characteristics curves (AUROC). Best pair ratios of general EVs/PEVs were used for univariate analysis, and top pairs were combined for multivariate analysis. Results were validated by comparison with EVs purified using standard procedures.

Results

Heatmaps differentiated surface profiles of preeclampsia, preterm delivery, and term delivery receptors on total EVs and PEVs. Similar results were obtained with enriched EVs and EVs from raw plasma. Univariate analyses identified markers predicting preterm delivery and preeclampsia over term delivery controls with AUC >0.6 and sensitivity >50% at 80% specificity. Combining the best markers in a multivariate model, preeclampsia prediction over term delivery had an AUC of 0.89 (95% CI: 0.72–1.0) with 90% sensitivity and 90% specificity, marked by inflammation (TNF RII), relaxation (placenta protein 13 (PP13)), and immune‐modulation (LFA1) receptors. Preterm delivery prediction over term delivery had an AUC of 0.97 (0.94–1.0), 84% sensitivity, and 90% specificity, marked by cell adhesion (ICAM), immune suppression, and general EV markers (CD81, CD82, and Alix). Preeclampsia prediction over preterm delivery had an AUC of 0.91 (0.79–0.99) with 80% sensitivity and 90% specificity with markers for complement activation (C1q) and autoimmunity markers.

Conclusions

The new, robust EV Multi‐Array analyzer and methodology offer a simple, fast diagnostic tool that reveals novel surface markers for major obstetric syndromes.

Subjects

MeSH terms (MEDLINE)

Extracellular VesiclesBiomarkersPre-EclampsiaHumansFemalePregnancyAdultProspective StudiesPremature BirthCase-Control StudiesMicroarray AnalysisIsraelPredictive Value of TestsSensitivity and SpecificityPlacenta

Author keywords

differential diagnosisextracellular vesiclesimmunodiagnosticsmicro arrayspreeclampsiapreterm deliverysurface markers

Substances

Biomarkers

Authors and institutions

  • Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Department of Obstetrics and Gynecology, Maternal and Fetal Medicine Unit, Bnai-Zion University Medical Center, Haifa, Israel.
  • Department of Statistics, Tel Hai Academic College, Tel Hai and Ziv Medical Center, Safed, Israel.
  • Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK.
  • TeleMarpe Ltd, Tel Aviv, Israel.

ORCID profiles: Malene Møller Jørgensen, Manu Vatish, Hamutal Meiri

Funding

  • COST Action
  • Braude College of Engineering, Research Collaboration Program

Cite

APA

Jørgensen, M. M., Bæk, R., Sloth, J. K., Sammour, R., Sharabi-Nov, A., Vatish, M., Meiri, H., & Sammar, M. (2025). A novel multiple marker microarray analyzer and methodology to predict major obstetric syndromes using surface markers of circulating extracellular vesicles from maternal plasma. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.15020

Vancouver

Jørgensen MM, Bæk R, Sloth JK, Sammour R, Sharabi-Nov A, Vatish M, et al. A novel multiple marker microarray analyzer and methodology to predict major obstetric syndromes using surface markers of circulating extracellular vesicles from maternal plasma. Acta Obstetricia et Gynecologica Scandinavica. 2025. doi:10.1111/aogs.15020

BibTeX
@article{Jrgensen2025,
  author = {Jørgensen, Malene Møller and Bæk, Rikke and Sloth, Jenni K and Sammour, Rami and Sharabi-Nov, Adi and Vatish, Manu and Meiri, Hamutal and Sammar, Marei},
  title = {A novel multiple marker microarray analyzer and methodology to predict major obstetric syndromes using surface markers of circulating extracellular vesicles from maternal plasma},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2025},
  doi = {10.1111/aogs.15020}
}
Start for free →